Page 33 - CASA Bulletin of Anesthesiology 2022; 9(5)

Vol. 9, No 5, 2022

of cannabis which contrasts most state legislation, and a lack of high-quality human studies to
guide perioperative decision-making.

References

1. Friedman D, Sirven JI. Historical perspective on the medical use of cannabis for epilepsy: Ancient times to the
1980s. Epilepsy & Behavior. 2017;70:298-301. doi:10.1016/j.yebeh.2016.11.033
2. Bonini SA, Premoli M, Tambaro S, et al. Cannabis sativa: A comprehensive ethnopharmacological review of a
medicinal plant with a long history. Journal of Ethnopharmacology. 2018;227:300-315.
doi:10.1016/j.jep.2018.09.004
3. General Medical Convention, National Convention for Revising the Pharmacopoeia, United States
Pharmacopoeial Convention, & Royal College of Physicians of London. (1851). The pharmacopoeia of the
United States of America, 1850. Philadelphia, Pennsylvania : Publisher not identified.
http://archive.org/details/b24907030.
4. US Drug Enforcement Agency. The Controlled Substances Act. http://www.dea.gov/controlled-substances-act;
accessed March 15, 2022.
5. US Drug Enforcement Agency. Drug scheduling. https://www.dea.gov/drug-information/drug-scheduling;
accessed March 15, 2022.
6. Battista N, Di Tommaso M, Bari M, Maccarrone M. The endocannabinoid system: an overview. Front Behav
Neurosci. 2012;6:9. doi:10.3389/fnbeh.2012.00009
7. Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the
Central Nervous System. Int J Mol Sci. 2018;19(3):833. doi:10.3390/ijms19030833
8. Yang H, Zhou J, Lehmann C. GPR55 – a putative “type 3” cannabinoid receptor in inflammation. Journal of
Basic and Clinical Physiology and Pharmacology. 2016;27(3):297-302. doi:10.1515/jbcpp-2015-0080
9. Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin
Pharmacol. 2018;84(11):2477-2482. doi:10.1111/bcp.13710
10. Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of
the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790-4805. doi:10.1111/bph.13250
11. Alexander JC, Joshi GP. A review of the anesthetic implications of marijuana use. Proc (Bayl Univ Med Cent).
2019;32(3):364-371. doi:10.1080/08998280.2019.1603034
12. Freeman AM, Petrilli K, Lees R, et al. How does cannabidiol (CBD) influence the acute effects of delta-9-
tetrahydrocannabinol (THC) in humans? A systematic review. Neuroscience & Biobehavioral Reviews.
2019;107:696-712. doi:10.1016/j.neubiorev.2019.09.036
13. Tapley P, Kellett S. Cannabis-based medicines and the perioperative physician. Perioper Med (Lond).
2019;8:19. doi:10.1186/s13741-019-0127-x
14. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J
Intern Med. 2018;49:12-19. doi:10.1016/j.ejim.2018.01.004
15. Davidson EM, Raz N, Eyal AM. Anesthetic considerations in medical cannabis patients. Curr Opin
Anaesthesiol. 2020;33(6):832-840. doi:10.1097/ACO.0000000000000932
16. World Health Organization. Division of Mental Health and Prevention of Substance Abuse. Cannabis: a health
perspective and research agenda.
https://apps.who.int/iris/bitstream/handle/10665/63691/WHO_MSA_PSA_97.4.pdf?sequence=1&isAllow
ed=y. Accessed March 15, 2022
17. Ladha KS, McLaren-Blades A, Goel A, et al. Perioperative Pain and Addiction Interdisciplinary Network
(PAIN): consensus recommendations for perioperative management of cannabis and cannabinoid-based
medicine users by a modified Delphi process. British Journal of Anaesthesia. 2021;126(1):304-318.
doi:10.1016/j.bja.2020.09.026

P a g e 32 | 66